Avalon Pharmaceuticals, Inc. (Nasdaq and NYSE Arca: AVRX), announced that it will present pharmacodymanic endpoint data from a phase I study of AVN944 at the American Society of Hematology's 48th Annual Meeting to be held on December 9-12, in Orlando. AVN944 is the Company's lead product candidate for the treatment of hematologic malignancies. Dr. [click link for full article]
More...